
Tesofensine is a triple monoamine reuptake inhibitor, acting on the noradrenaline, dopamine and serotonin transporters. It has been examined in clinical research for its effect on energy intake. Supplied as pre-dosed tablets.
| Form | Oral capsules — pre-dosed, no reconstitution |
| Purity | ≥99% (verified) |
| Storage | Cool and dry, sealed; protect from light |
| Batch | COA available on request |
Tesofensine is a triple monoamine reuptake inhibitor, acting on the noradrenaline, dopamine and serotonin transporters. It has been examined in clinical research for its effect on energy intake. Supplied as pre-dosed tablets.
Tesofensine is a triple monoamine reuptake inhibitor, blocking the transporters for noradrenaline, dopamine and serotonin. Inhibiting all three distinguishes it from the selective reuptake inhibitors that dominate this drug class.
It has an unusual development history. Originally investigated for neurological indications including Parkinson's and Alzheimer's disease, it failed to meet its primary endpoints — but reduced energy intake observed during those trials redirected the programme entirely toward metabolic research.
Supplied as pre-dosed tablets for laboratory research use only. Not for human consumption.
By blocking the noradrenaline, dopamine and serotonin transporters simultaneously, tesofensine raises synaptic availability of all three monoamines. Most clinical reuptake inhibitors target one or two; the three-way profile is what makes it pharmacologically distinctive.
Unlike most compounds in this catalogue, tesofensine has published randomised controlled data in humans from its metabolic development programme. The evidence base is therefore clinical rather than purely preclinical.
Research has examined whether the effect on intake is driven predominantly by the noradrenergic component, the dopaminergic one, or their interaction — the question being which transporter contributes what.
The shift from a failed neurological programme to metabolic research is itself documented in the literature and is a frequently cited case study in drug repurposing.
Tesofensine has published Phase 2 human data but has not completed Phase 3 development and is not approved in the United States. Monoamine reuptake inhibitors carry cardiovascular and psychiatric considerations that are a substantial part of the published discussion.
| State | Temperature | Practical shelf life |
|---|---|---|
| Sealed bottle, room temperature | 15–25 °C | To printed expiry |
| Sealed bottle, refrigerated | 2–8 °C | To printed expiry |
| Opened bottle, tightly closed | 15–25 °C | Months, if kept dry |
| Exposed to humidity | any | Degrades — discard |
Oral dosage forms are considerably more forgiving than lyophilized peptides. Capsules and tablets are stable at room temperature and require no cold chain, in transit or in storage.
Moisture is the real enemy rather than temperature. Keep the bottle tightly closed, leave the desiccant sachet in place, and avoid storing in a bathroom or anywhere humidity swings. Protect from direct light.
Every lot is tested by an independent laboratory before release. HPLC establishes purity as a percentage of total content, separating the target compound from synthesis by-products; mass spectrometry confirms molecular identity.
For an encapsulated product there is a second question a vial does not raise: content uniformity. A capsule can be the right compound at the right purity and still be filled inconsistently, so Tesofensine is checked for fill weight consistency across the batch as well as for identity and purity.
The certificate of analysis references the lot number printed on your bottle label. Request it at [email protected].
Join the list for restock notifications on high-demand compounds, new lot announcements with COA links, and subscriber-only pricing.